A Review of FDA Draft Guidance on PROs in Oncology Trials

Signant’s in-house clinical and digital health sciences experts discuss the key takeaways from the FDA’s draft guidance on the use of patient-reported outcomes in oncology clinical trials. 

Watch the webinar recording to learn current patient-reported outcome measures (PROMs) labeling and oncology challenges, including:

• How to address PROM specificity
• Core measurement domains
• Ideal measurement timing and frequency
• Implications for eCOA design and implementation

Discover key recommendations, compliance strategies, and how technology can enhance data quality and patient-centric trial design.